Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.…
Does Gossamer Bio (GOSS) Have the Potential to Rally 659.56% as Wall Street Analysts Expect?
Gossamer Bio (NASDAQ: GOSS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 161 employees.
The shares were at 10.72 USD on 20 November 2026, down 94.3% over 52 weeks. Its 52-week range is 8.300 USD to 309.60 USD: the price is 96.5% below the high and 29.2% above the low.
Its market capitalisation is 65.57M USD.
Gossamer Bio reports return on equity of 138.8%, an operating margin of -136.5% and revenue up 189.1% year over year.
It holds more cash than debt, a net cash position of 16.96M USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. The next earnings report is expected on 17 March 2027.